Abstract
Background: Recent trials of platelet glycoprotein IIb/IIIa receptor inhibitors have improved our understanding
to best use these powerful antiplatelet drugs in acute coronary syndrome. We tested the hypothesis that inhibition
of GPIIb/IIIa platelet receptor with Eptifibatide is effective as an empiric therapy in patients with acute coronary
syndrome who do not necessarily undergo immediate revascularization.
Methods: Since Feb 2006 one hundred and ninety-six patients who had presented with non ST-elevation acute
coronary syndrome (NSTE-ACS) were randomly assigned to receive Eptifibatide in addition to standard therapy,
for up to 72 hours or routine standard therapy. The primary end point was composite of death and non-fatal
myocardial infarction (MI) or urgent target vessel revascularization (TVR) in 30 days.
Results: The incidence of composite end point of death, non fatal MI and urgent TVR was significantly lower in
Eptifibatide group than standard group (16% vs. 0% - P value <0.01),particularly in troponin positive subgroup
of patients (27.8% vs. 0% - P value <0.01).
Any major adverse reaction such as major bleeding, stroke, or thrombocytopenia was not seen.
Conclusion: Early administration of GP IIb/IIIa receptor inhibitor is recommended in patients with high-risk
acute coronary syndrome.
to best use these powerful antiplatelet drugs in acute coronary syndrome. We tested the hypothesis that inhibition
of GPIIb/IIIa platelet receptor with Eptifibatide is effective as an empiric therapy in patients with acute coronary
syndrome who do not necessarily undergo immediate revascularization.
Methods: Since Feb 2006 one hundred and ninety-six patients who had presented with non ST-elevation acute
coronary syndrome (NSTE-ACS) were randomly assigned to receive Eptifibatide in addition to standard therapy,
for up to 72 hours or routine standard therapy. The primary end point was composite of death and non-fatal
myocardial infarction (MI) or urgent target vessel revascularization (TVR) in 30 days.
Results: The incidence of composite end point of death, non fatal MI and urgent TVR was significantly lower in
Eptifibatide group than standard group (16% vs. 0% - P value <0.01),particularly in troponin positive subgroup
of patients (27.8% vs. 0% - P value <0.01).
Any major adverse reaction such as major bleeding, stroke, or thrombocytopenia was not seen.
Conclusion: Early administration of GP IIb/IIIa receptor inhibitor is recommended in patients with high-risk
acute coronary syndrome.
Keywords
GP IIb/IIIa Receptor Inhibitor Eptifibatide Acute Coronary Syndrome
Fulltext
The full text is available in PDF.
References
-
1.
The references are available in PDF.
Copyright
© 2009, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.